A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Ipilimumab (Primary) ; Tilsotolimod (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE 301
- Sponsors Idera Pharmaceuticals
- 06 Nov 2018 According to an Idera Pharmaceuticals media release, 42 of the planned up to 110 sites across 12 countries have been activated for the randomization of patients into the trial.
- 22 Oct 2018 Planned End Date changed from 1 Jul 2020 to 1 Jun 2022.
- 22 Oct 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Nov 2021.